Monitoring of Implant Diseases: Diagnosis and Monitoring With aMMP-8 Test Technology
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Peri-Implantitis and Peri-implant mucositis.
- Who it may be relevant to
- Registry conditions: Peri-Implant Health, Peri-Implantitis and Peri-implant Mucositis. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Finland
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Monitoring of Implant Diseases: Diagnosis and Monitoring With aMMP-8 Test Technology: A 5-year Follow-up Study
Overview
68 patients underwent the aMMP-8 chair-side test as well as clinical traditional measurement methods. Those who had one or more implants in their mouth were selected as patients. The condition of the attachment tissues of these implants is monitored at a control visit after five years.
Detailed description
Patients who arrive for maintenance follow-up are included in the study. The trational measurement technique is used to follow the health of peri-implant tissues.
Interventions
- Diagnostic test Peri-Implantitis and Peri-implant mucositis
peri-implant mucositis, peri-implantitis
Primary outcome measures
- Tratitional measurement [Time frame: 5 years]
- Traditional measure [Time frame: through study completion, an average of 5 year]
- Biomarker test [Time frame: through study completion, an average of 5 year]
Eligibility criteria
Inclusion criteria
- the participation previously study implant patient
Exclusion criteria
- has not received antibiotic treatment within 6 months
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Screening
Study locations
Finland · 1 center
- Department of Oral and Maxillofacial Diseases, Head and Neck Center — Helsinki
Publications
- Lahteenmaki H, Umeizudike KA, Heikkinen AM, Raisanen IT, Rathnayake N, Johannsen G, Tervahartiala T, Nwhator SO, Sorsa T. aMMP-8 Point-of-Care/Chairside Oral Fluid Technology as a Rapid, Non-Invasive Tool for Periodontitis and Peri-Implantitis Screening in a Medical Care Setting. Diagnostics (Basel). 2020 Aug 5;10(8):562. doi: 10.3390/diagnostics10080562. PMID 32764436
- Natto ZS, Almeganni N, Alnakeeb E, Bukhari Z, Jan R, Iacono VJ. Peri-Implantitis and Peri-Implant Mucositis Case Definitions in Dental Research: A Systematic Assessment. J Oral Implantol. 2019 Apr;45(2):127-131. doi: 10.1563/aaid-joi-D-18-00097. Epub 2018 Dec 17. PMID 30557088
- Sorsa T, Tervahartiala T, Leppilahti J, Hernandez M, Gamonal J, Tuomainen AM, Lauhio A, Pussinen PJ, Mantyla P. Collagenase-2 (MMP-8) as a point-of-care biomarker in periodontitis and cardiovascular diseases. Therapeutic response to non-antimicrobial properties of tetracyclines. Pharmacol Res. 2011 Feb;63(2):108-13. doi: 10.1016/j.phrs.2010.10.005. Epub 2010 Oct 16. PMID 20937384
- Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. J Periodontol. 2018 Jun;89 Suppl 1:S159-S172. doi: 10.1002/JPER.18-0006. PMID 29926952
Identifiers
NCT: NCT06761521 · 20092024